Insmed Inc (INSM) - Total Assets
Based on the latest financial reports, Insmed Inc (INSM) holds total assets worth $2.36 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Insmed Inc for net asset value and shareholders' equity analysis.
Insmed Inc - Total Assets Trend (1999–2024)
This chart illustrates how Insmed Inc's total assets have evolved over time, based on quarterly financial data.
Insmed Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Insmed Inc's total assets of $2.36 Billion consist of 80.1% current assets and 19.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.4% |
| Accounts Receivable | $52.01 Million | 2.6% |
| Inventory | $98.58 Million | 4.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $58.65 Million | 2.9% |
| Goodwill | $136.11 Million | 6.7% |
Asset Composition Trend (1999–2024)
This chart illustrates how Insmed Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Insmed Inc (INSM) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Insmed Inc's current assets represent 80.1% of total assets in 2024, a decrease from 88.4% in 1999.
- Cash Position: Cash and equivalents constituted 27.4% of total assets in 2024, up from 6.0% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is goodwill at 6.7% of total assets.
Insmed Inc Competitors by Total Assets
Key competitors of Insmed Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Insmed Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.63 | 6.37 | 5.24 |
| Quick Ratio | 4.34 | 5.99 | 4.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.51 Billion | $1.39 Billion | $504.08 Million |
Insmed Inc - Advanced Valuation Insights
This section examines the relationship between Insmed Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 33.59 |
| Latest Market Cap to Assets Ratio | 14.03 |
| Asset Growth Rate (YoY) | 52.3% |
| Total Assets | $2.03 Billion |
| Market Capitalization | $28.42 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Insmed Inc's assets at a significant premium (14.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Insmed Inc's assets grew by 52.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Insmed Inc (1999–2024)
The table below shows the annual total assets of Insmed Inc from 1999 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.03 Billion | +52.29% |
| 2023-12-31 | $1.33 Billion | -19.72% |
| 2022-12-31 | $1.66 Billion | +33.21% |
| 2021-12-31 | $1.24 Billion | +56.19% |
| 2020-12-31 | $796.15 Million | +7.26% |
| 2019-12-31 | $742.30 Million | +22.78% |
| 2018-12-31 | $604.56 Million | +30.84% |
| 2017-12-31 | $462.05 Million | +94.17% |
| 2016-12-31 | $237.96 Million | -33.26% |
| 2015-12-31 | $356.56 Million | +54.44% |
| 2014-12-31 | $230.86 Million | +30.80% |
| 2013-12-31 | $176.50 Million | +14.94% |
| 2012-12-31 | $153.56 Million | +9.82% |
| 2011-12-31 | $139.83 Million | -28.75% |
| 2010-12-31 | $196.26 Million | +54.91% |
| 2009-12-31 | $126.69 Million | +2562.78% |
| 2008-12-31 | $4.76 Million | -75.60% |
| 2007-12-31 | $19.50 Million | -31.21% |
| 2006-12-31 | $28.35 Million | +23.95% |
| 2005-12-31 | $22.87 Million | +75.77% |
| 2004-12-31 | $13.01 Million | -56.36% |
| 2003-12-31 | $29.81 Million | +5.31% |
| 2002-12-31 | $28.31 Million | -60.47% |
| 2001-12-31 | $71.61 Million | -30.29% |
| 2000-12-31 | $102.72 Million | +1839.71% |
| 1999-12-31 | $5.30 Million | -- |
About Insmed Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antiba… Read more